4-Ethyl-3-pyridin-3-ylmorpholine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-Ethyl-3-pyridin-3-ylmorpholine
• 英文别名: 4-ethyl-3-pyridin-3-ylmorpholine
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.26
• InChiKey: IXNKVIPTCZTPJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES<br/>[FR] IMIDAZOPYRIDINES À SUBSTITUTION ISOXAZOLYLE
  申请人：CELLCENTRIC LTD

  公开号：WO2016170323A1

  公开（公告）日：2016-10-27

  A compound which is an isoxazolyl imidazopyridine of formula (I): wherein: R0 and R, which are the same or different, are each H or C alkyl; R9' and R9", which are the same or different, are each H or F; X is -(alk)n-, -alk-C(=O)-NR-, -alk-NR-C(=O)- or -alk-C(=O)-; R1 is selected from -S(=O)2R' and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; R2 and R2', which are the same or different, are each H or C1-6 alkyl; or R2 and R2' form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3', which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R' is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer.

  一种具有如下结构的异噁唑基咪唑吡啶化合物（I）：其中：R0和R，相同或不同，各自为H或C烷基；R9'和R9"，相同或不同，各自为H或F；X为-(烷基)n-、-烷基-C(=O)-NR-、-烷基-NR-C(=O)-或-烷基-C(=O)-；R1选自-S(=O)2R'和未取代或取代的4至7成员杂环基；R2和R2'，相同或不同，各自为H或C1-6烷基；或R2和R2'与它们附着的C原子共同形成C3-6环烷基；R3和R3'，相同或不同，各自为H、C1-6烷基、OH或F；R4为苯基或未取代或取代的5至12成员含氮杂环基；烷基为C1-6烷基；R'为C1-6烷基；n为0或1；或其在药学上可接受的盐。该化合物具有调节p300和/或CBP活性的作用，并用于治疗癌症。
• Method of treatment using substituted imidazo[1,2b]pyridazine compounds
  申请人：Array BioPharma, Inc.

  公开号：US10011604B2

  公开（公告）日：2018-07-03

  Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.

  用于治疗哺乳动物疼痛、癌症、炎症、神经退行性疾病、克氏扁虱感染和溶骨性疾病中的疾病或紊乱的方法，包括向所述哺乳动物施用治疗有效量的式 I 化合物 其中 R1、R2、R3、R4、X、Y 和 n 具有说明书中给出的含义。
• ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES
  申请人：Cellcentric Ltd

  公开号：EP3286188A1

  公开（公告）日：2018-02-28